Table 5.
Clinical sensitivity and specificity based on days PSO.
Evaluation Results of Test Equipment (GenBody COVID-19 Kit) | Confirmed Results through RT-PCR Positive |
||||||||
---|---|---|---|---|---|---|---|---|---|
0–6 Days PSO | 7–13 Days PSO | ≥14 Days PSO | |||||||
IgM/IgG | IgM | IgG | IgM/IgG | IgM | IgG | IgM/IgG | IgM | IgG | |
Positive | 11 | 10 | 11 | 27 | 23 | 27 | 89 | 74 | 89 |
Negative | 03 | 04 | 03 | 00 | 04 | 00 | 00 | 15 | 00 |
Total | 14 | 14 | 14 | 27 | 27 | 27 | 89 | 89 | 89 |
Sensitivity | 78.57% | 71.43% | 78.57% | 100.00% | 85.19% | 100.00% | 100.00% | 83.15% | 100.00% |
95% CI | 49.20~95.34% | 41.90%~91.61% | 49.20~95.34% | 87.23~100.00% | 66.27~100.00% | 87.23~100.00% | 95.94~100.00% | 73.73~90.25% | 95.94~100.00% |
PSO, post symptom onset.